EE200000653A - Bensotiofeenid, bensofuraanid ja indoolid kasutamiseks insuliiniresistentsuse ning hüperglükeemia ravis - Google Patents

Bensotiofeenid, bensofuraanid ja indoolid kasutamiseks insuliiniresistentsuse ning hüperglükeemia ravis

Info

Publication number
EE200000653A
EE200000653A EEP200000653A EEP200000653A EE200000653A EE 200000653 A EE200000653 A EE 200000653A EE P200000653 A EEP200000653 A EE P200000653A EE P200000653 A EEP200000653 A EE P200000653A EE 200000653 A EE200000653 A EE 200000653A
Authority
EE
Estonia
Prior art keywords
benzothiophenes
benzofurans
hyperglycaemia
indoles
treatment
Prior art date
Application number
EEP200000653A
Other languages
English (en)
Estonian (et)
Inventor
Edward Wrobel Jay
Joan Dietrich Arlene
Miyoko Antane Madelene
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of EE200000653A publication Critical patent/EE200000653A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
EEP200000653A 1998-05-12 1999-05-10 Bensotiofeenid, bensofuraanid ja indoolid kasutamiseks insuliiniresistentsuse ning hüperglükeemia ravis EE200000653A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12
PCT/US1999/010209 WO1999061435A1 (en) 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia

Publications (1)

Publication Number Publication Date
EE200000653A true EE200000653A (et) 2002-04-15

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000653A EE200000653A (et) 1998-05-12 1999-05-10 Bensotiofeenid, bensofuraanid ja indoolid kasutamiseks insuliiniresistentsuse ning hüperglükeemia ravis

Country Status (22)

Country Link
EP (1) EP1077969A1 (xx)
JP (1) JP2002516321A (xx)
KR (1) KR20010043539A (xx)
CN (1) CN1308626A (xx)
AR (1) AR015294A1 (xx)
AU (1) AU756337B2 (xx)
BG (1) BG104918A (xx)
BR (1) BR9911779A (xx)
CA (1) CA2330620A1 (xx)
EA (1) EA200001175A1 (xx)
EE (1) EE200000653A (xx)
HR (1) HRP20000767A2 (xx)
HU (1) HUP0101792A3 (xx)
ID (1) ID26244A (xx)
IL (1) IL139132A0 (xx)
NO (1) NO20005677L (xx)
PL (1) PL344081A1 (xx)
SK (1) SK16992000A3 (xx)
TR (1) TR200003333T2 (xx)
TW (1) TW510900B (xx)
WO (1) WO1999061435A1 (xx)
ZA (1) ZA200005961B (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002026707A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Novel compounds
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
WO2002098410A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and a sulfonylurea agent
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
WO2002098408A1 (en) * 2001-06-07 2002-12-12 Wyeth Ptpase inhibitors for improving cardiovascular risk profile
WO2002100398A1 (en) * 2001-06-07 2002-12-19 Wyeth Combination of a ptpase inhibitor and an ace inhibitor
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7022730B2 (en) 2001-10-19 2006-04-04 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
WO2003048140A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
ITMI20022172A1 (it) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa Processo per la preparazione di 3-alchil-tiofeni-2, 5-disostituiti.
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
DE60327550D1 (de) 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60306547T2 (de) 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
EP1569901B1 (en) 2002-12-10 2008-10-15 Wyeth ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法
CN107033122B (zh) * 2017-05-19 2019-06-14 南方医科大学 一种n-芳基-2-噻吩酰胺类衍生物及其制备方法和用途
US20210115397A1 (en) 2018-04-26 2021-04-22 Tokyo Institute Of Technology Method for promoting differentiation of pluripotent stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015724B1 (xx) * 1968-08-15 1973-01-12 Parke Davis & Co
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
JPH01135766A (ja) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd ビフェニル誘導体
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
KR20010043539A (ko) 2001-05-25
AR015294A1 (es) 2001-04-18
AU3893999A (en) 1999-12-13
NO20005677D0 (no) 2000-11-10
TR200003333T2 (tr) 2001-02-21
EP1077969A1 (en) 2001-02-28
HRP20000767A2 (en) 2001-10-31
ID26244A (id) 2000-12-07
EA200001175A1 (ru) 2001-06-25
JP2002516321A (ja) 2002-06-04
IL139132A0 (en) 2001-11-25
PL344081A1 (en) 2001-09-24
HUP0101792A2 (hu) 2002-01-28
SK16992000A3 (sk) 2001-04-09
HUP0101792A3 (en) 2003-01-28
CA2330620A1 (en) 1999-12-02
ZA200005961B (en) 2001-10-24
BG104918A (bg) 2001-08-31
NO20005677L (no) 2000-12-05
WO1999061435A1 (en) 1999-12-02
CN1308626A (zh) 2001-08-15
BR9911779A (pt) 2001-02-06
AU756337B2 (en) 2003-01-09
TW510900B (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EE200000653A (et) Bensotiofeenid, bensofuraanid ja indoolid kasutamiseks insuliiniresistentsuse ning hüperglükeemia ravis
NO991186L (no) Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
PT1322163E (pt) Tratamento de sementes com combinacoes de piretrinas/piretroides e clotianidina
DE60033051D1 (de) Methode und einrichtung zur kontinuierlichen herstellung von diarylcarbonaten
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
DE69921429D1 (de) Dreh- und steuerbares Bohrsystem mit Schiebehülse
DE69727345D1 (de) Substratbehandlungsanordnung, Substratübertragungsanordnung und Methode
NO20013883D0 (no) Frysetorket middel inneholdende paramylon, samt fremgangsmate og anvendelse derav
EE200100437A (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
NO20005990D0 (no) Platinumkompleks, dets fremstilling og terapeutiske anvendelse
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
DE69923044D1 (de) Gewebebehandlungsmittel, Gewebe, Textildruckverfahren sowie Druck
FI980472A (fi) Latausmenetelmä ja -järjestely
ATE337321T1 (de) Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
FI981475A0 (fi) Menetelmät, laitteet ja kuvausmoodi tomografiakuvantamisessa
FI981476A0 (fi) Menetelmä, laite ja niiden käyttö tomografiakuvantamisessa
NO20005919L (no) Platinakompleks, dets fremstilling og terapeutisk anvendelse
DE69735123D1 (de) Trehalose phosphorylase, deren Herstellung und Verwendung
EP1117675A4 (en) THE KADHERING SIMILAR PROTEIN AND METHOD FOR ITS MANUFACTURE
FI981477A (fi) Menetelmä, laite ja niiden käyttö tomografiakuvantamisessa